The Mood and Anxiety Disorders Program (MAP) is committed to research that will advance the treatment of depression disorders in a number of areas. Our pharmaceutical studies include exploring novel uses for existing medications such as ketamine (an FDA-approved anesthetic with promising antidepressant effects) and developing new drugs. We are also researching more effective ways to use device-based therapies such as Transcranial Magnetic Stimulation (TMS), in which a magnetic coil is placed against the forehead to stimulate nerves in the brain. Our research into psychotherapy involves studies of new cognitive strategies.
In addition to researching new treatments, MAP is using neuroimaging studies including functional MRI (fMRI) to investigate brain activity during depression in order to better understand the biology of this condition.
Clinical Trials for Depression Disorders
MAP is currently seeking individuals interested in participating in the following clinical trials for depression:
- Continuation IV Ketamine in Major Depressive Disorder: Tests the antidepressant effect of intravenous (IV) ketamine given for one week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant depression.
- An fMRI Study of Ketamine in Treatment-Resistant Depression: Uses fMRI to investigate the neurobiological mechanisms of the antidepressant effects of ketamine in patients with treatment-resistant major depression.
- Intranasal Ketamine in Treatment-Resistant Depression: Studies the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression.
- Cognitive Training for Depression: Investigates the effectiveness of a computerized training program to help depressed individuals modify the negative bias with which they perceive and process information.
- Study Drug SPD489 used in Combination with an Antidepressant in Major Depressive Disorder: Investigates whether study drug SPD489 helps to improve depression symptoms as an augmentation treatment when added to an antidepressant medication.
- Low Field Magnetic Stimulation (LFMS) Augmentation of Antidepressant Therapy in Treatment-Resistant Depression: The purpose of this study is to look at the efficacy and safety of Low Field Magnetic Stimulation (LFMS) as a rapid antidepressant treatment for patients with hard to treat depression who are currently on an antidepressant medication.
- Nuedexta to Target the NMDA Glutamate Receptor in Treatment-Resistant Major Depression: The purpose of the current study is to investigate the safety, tolerability, and efficacy of Nuedexta as a novel antidepressant treatment for individuals suffering from Treatment Resistant Major Depressive Disorder and who have inadequately responded to antidepressant therapy in the past.
- Dopamine and Motivation in Depression: Studies the low reward motivation in patients with major depressive disorder by focusing on levels of dopamine in the brain. Patients undergo MRI and PET scans and receive Pramipexole (Mirapex) treatment over the course of 6 weeks at Mount Sinai.
- A Proof-Of-Concept Clinical Trial of a Novel KCNQ Potentiator in Major Depressive Disorder: Studies the safety tolerability and efficacy of ezogabine as a new antidepressant treatment for Major Depressive Disorder. Ezogabine is FDA-approved and given to patients as a take-home medication. Participation in this study lasts about 12 weeks.
To participate in one of our clinical trials for Mood and Anxiety Disorders or to learn more about eligibility, please contact Cara Levitch (212-241-3116; firstname.lastname@example.org).